Cloudbreak Therapeutics
Cloudbreak Therapeutics: A biotech firm repurposing approved drugs to treat eye diseases, utilizing a capital-efficient model.
Cloudbreak Therapeutics: A biotech firm repurposing approved drugs to treat eye diseases, utilizing a capital-efficient model.
Cloudbreak Therapeutics, founded with a mission to innovate ocular drug development, is a clinical-stage biotechnology company. The company repurposes approved systemic drugs for ocular delivery to treat various eye diseases. Utilizing a capital-efficient business model based on VIC and 505(b)(2) pathways, Cloudbreak aims to quickly advance drug candidates through Phase II clinical trials and out-license global rights for further development and commercialization. Their product pipeline includes treatments for conditions such as pterygium, myopia progression, MGD, pinguecula, and diabetic macular edema.
Notable figures affiliated with Cloudbreak Therapeutics include an experienced management team and a distinguished scientific advisory board. The company has achieved significant milestones, including advancing multiple drug candidates to proof-of-concept Phase II clinical trials. Cloudbreak's innovative approach has positioned it as a promising player in the biotechnology sector, potentially transforming the treatment landscape for ocular diseases and improving patient outcomes globally.
Companies similar to Cloudbreak Therapeutics include EyeCyte, OcuCure Therapeutics, Hyperion DeFi and Clearside Biomedical.
Cloudbreak Therapeutics was founded in 2015.
Cloudbreak Therapeutics' headquarters is located in Irvine, CA, US.
Cloudbreak Therapeutics' most recent funding round was for $130M (USD) in January 2022.
As of Jan 1, 2022, Cloudbreak Therapeutics has disclosed funding of $171.2M (USD). Undisclosed round amounts are excluded.
Cloudbreak Therapeutics has 30 employees as of Feb 4, 2024.

Clearside Biomedical
clearsidebio.com